Skip to content

BIO FRONTIER

  • Home
  • Artificial intelligence
  • Biotechnology
  • Genetics
  • Medical Technology
    • Home
    • Uncategorized
    • Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug

Gilead and Arcus halt late-stage study for anti-TIGIT cancer drug

Dec 12, 2025

Post navigation

Strategic Partnership | Sanyou Bio and KanryBio Forge Partnership to Co-Develop Key Reagents and Products for Biomarker Assay Kits
AusperBio Announces AHB-137 Monotherapy Achieved 30% Functional Cure Rate in HBe-negative CHB Patients on Stable Nucleos(t)ide Analogue (NA) Therapy
  • PR Newswire
  • GlobeNewswire
  • Contact
  • Privacy Policy

BIO FRONTIER

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.